Exelixis, Inc. (EXEL)
| Market Cap | 11.94B |
| Revenue (ttm) | 2.29B |
| Net Income (ttm) | 677.90M |
| Shares Out | 269.20M |
| EPS (ttm) | 2.38 |
| PE Ratio | 18.67 |
| Forward PE | 14.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,193,588 |
| Open | 44.20 |
| Previous Close | 44.37 |
| Day's Range | 43.85 - 44.59 |
| 52-Week Range | 31.90 - 49.62 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 44.73 (+0.83%) |
| Earnings Date | Nov 4, 2025 |
About EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $44.73, which is an increase of 0.83% from the latest price.
News
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesda...
2 Under-the-Radar Stocks to Buy Heading Into 2026
Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Exelixis, Inc. ( EXEL) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference C...
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but i...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim...
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript
Exelixis, Inc. ( EXEL) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Michael Morrissey - CEO,...
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At ...
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizu...
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placeb...
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to b...
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Partic...
Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 8:00 AM EDT Company Participants Christopher Senner - Executive VP & CFO Andrew Peters - Senio...
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call P...
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Exe...
Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL) Citi's Biopharma Back to School Conference September 3, 2025 3:15 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants D...
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Exelixis, Inc. (NASDAQ:EXEL) 2025 Wells Fargo Healthcare Conference September 3, 2025 12:45 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Dere...
Exelixis Announces Appointment of Dana T. Aftab, Ph.D.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. ...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: 2025 Well...
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters
CABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows...
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib alt...
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
Exelixis Inc. EXEL on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ET Company Participants l - Corporate Participant Amy C. Peterson - Executive VP of Product Development & Medical A...